Expert opinion on criteria for application of focal therapy

The  statements that you will find below represent the “expert opinion” of a multinational group of specialists who have been using focal therapy investigationally in the treatment of men with certain types of prostate cancer in recent years. … READ MORE …

TRT and prostate cancer risk in hypogonadal men

A new paper in the Journal of Urology provides data from European males with clinically low levels of serum testosterone indicating that, in these patients, testosterone replacement therapy (TRT) was not associated with any increase in risk for a diagnosis of prostate cancer. … READ MORE …

A compound genetic/genomic and microenvironmental risk classification for localized prostate cancer

As we become more knowledgeable about the underlying genetic and other factors that affect the risk for, and the risk for progression of, apparently localized prostate cancer, we also become more able to predict such risks … but this is a very complex topic. … READ MORE …

Family history and screening for prostate cancer: no evidence of benefit

In what we believe to be the first report of its kind from anywhere in the world, a new paper has reported that there seems to be no evidence that selective screening of men with a family history of prostate cancer is clinically beneficial compared to men with no family history of prostate cancer. … READ MORE …

Active surveillance for men with Gleason 3 + 4 = 7 disease

The “New” Prostate Cancer InfoLink has taken the position for quite a while that active surveillance could well be a highly appropriate management strategy for some men  with a Gleason score of 3 + 4 = 7 at diagnosis (but far from all of them) — if they still met certain other criteria as good candidates for this form of management. … READ MORE …

The value of the PCTRF comparative outcomes data

The “New” Prostate Cancer InfoLink wants to be clear for our readers that we are significantly less enthusiastic than others about some of the information being offered to patients, clinicians, and payers through the web site of an organization known as the Prostate Cancer Treatment Research Foundation (PCTRF). … READ MORE …

A future with too many tests and no comparative data about value?

The role of personalized genetic and genomic testing and the value of such testing to test to accurately and reliably predict things like the appropriateness of active surveillance as a management strategy or the risk for recurrence after first-line surgery is now evolving at almost bewildering speed. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,175 other followers